$1.6 Billion is the total value of Rock Springs Capital Management LP's 137 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AET | AETNA INC NEW | $50,810,000 | -5.5% | 440,100 | 0.0% | 3.18% | -20.0% | |
| PFE | PFIZER INC | $35,760,000 | -3.8% | 1,055,800 | 0.0% | 2.24% | -18.5% | |
| HCA | HCA HOLDINGS INC | $32,521,000 | -1.8% | 430,000 | 0.0% | 2.04% | -16.8% | |
| WCG | WELLCARE HEALTH PLANS INC | $27,458,000 | +9.1% | 234,500 | 0.0% | 1.72% | -7.6% | |
| CELG | CELGENE CORP | $26,603,000 | +6.0% | 254,500 | 0.0% | 1.67% | -10.2% | |
| LLY | LILLY ELI & CO | $22,152,000 | +1.9% | 276,000 | 0.0% | 1.39% | -13.7% | |
| PRTA | PROTHENA CORP PLC | $18,471,000 | +71.5% | 308,000 | 0.0% | 1.16% | +45.3% | |
| AMGN | AMGEN INC | $15,680,000 | +9.6% | 94,000 | 0.0% | 0.98% | -7.2% | |
| PRAH | PRA HEALTH SCIENCES INC | $14,297,000 | +35.3% | 253,000 | 0.0% | 0.90% | +14.6% | |
| GLPG | GALAPAGOS NVspon adr | $13,579,000 | +16.6% | 210,000 | 0.0% | 0.85% | -1.3% | |
| HLS | HEALTHSOUTH CORP | $10,751,000 | +4.5% | 265,000 | 0.0% | 0.67% | -11.5% | |
| HRC | HILL ROM HLDGS INC | $7,438,000 | +22.9% | 120,000 | 0.0% | 0.47% | +4.0% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $7,403,000 | +15.4% | 450,000 | 0.0% | 0.46% | -2.3% | |
| BGNE | BEIGENE LTDsponsored adr | $6,932,000 | +3.4% | 225,000 | 0.0% | 0.44% | -12.3% | |
| REGN | REGENERON PHARMACEUTICALS | $6,834,000 | +15.1% | 17,000 | 0.0% | 0.43% | -2.7% | |
| MGNX | MACROGENICS INC | $6,730,000 | +10.8% | 225,000 | 0.0% | 0.42% | -6.2% | |
| EGALET CORPnote 5.500% 4/0 | $6,684,000 | +12.8% | 7,800,000 | 0.0% | 0.42% | -4.3% | ||
| EVHC | ENVISION HEALTHCARE HLDGS IN | $6,481,000 | -12.2% | 291,000 | 0.0% | 0.41% | -25.8% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $6,421,000 | +17.6% | 555,000 | 0.0% | 0.40% | -0.2% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $6,030,000 | +51.5% | 300,000 | 0.0% | 0.38% | +28.1% | |
| JUNO | JUNO THERAPEUTICS INC | $5,912,000 | -21.9% | 197,001 | 0.0% | 0.37% | -33.9% | |
| RTIX | RTI SURGICAL INC | $5,822,000 | -12.8% | 1,860,000 | 0.0% | 0.36% | -26.1% | |
| ATHN | ATHENAHEALTH INC | $5,770,000 | -8.6% | 45,750 | 0.0% | 0.36% | -22.5% | |
| ADRO | ADURO BIOTECH INC | $5,158,000 | +9.9% | 415,000 | 0.0% | 0.32% | -7.2% | |
| TNDM | TANDEM DIABETES CARE INC | $4,558,000 | +1.6% | 595,000 | 0.0% | 0.29% | -13.9% | |
| CLVS | CLOVIS ONCOLOGY INC | $4,506,000 | +162.7% | 125,000 | 0.0% | 0.28% | +122.0% | |
| CO | CHINA CORD BLOOD CORP | $4,497,000 | -11.1% | 880,000 | 0.0% | 0.28% | -24.8% | |
| AIMT | AIMMUNE THERAPEUTICS INC | $4,395,000 | +38.6% | 293,000 | 0.0% | 0.28% | +17.4% | |
| AGNPRA | ALLERGAN PLCpfd conv ser a | $4,106,000 | -1.4% | 5,000 | 0.0% | 0.26% | -16.6% | |
| NVLS | NIVALIS THERAPEUTICS INC | $3,976,000 | +76.8% | 489,000 | 0.0% | 0.25% | +50.0% | |
| MEDICINES COnote 2.500% 1/1 | $3,898,000 | +9.8% | 3,000,000 | 0.0% | 0.24% | -7.2% | ||
| CRME | CARDIOME PHARMA CORP | $3,751,000 | -38.9% | 1,200,000 | 0.0% | 0.24% | -48.4% | |
| INVA | INNOVIVA INC | $3,703,000 | +4.4% | 336,900 | 0.0% | 0.23% | -11.8% | |
| PRGO | PERRIGO CO PLC | $3,499,000 | +1.8% | 37,900 | 0.0% | 0.22% | -13.8% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $3,359,000 | +31.9% | 524,089 | 0.0% | 0.21% | +11.6% | |
| NBRV | NABRIVA THERAPEUTICS AGsponsored adr | $3,003,000 | -6.0% | 426,000 | 0.0% | 0.19% | -20.7% | |
| STE | STERIS PLC | $2,924,000 | +6.3% | 40,000 | 0.0% | 0.18% | -10.3% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $2,896,000 | -60.7% | 190,000 | 0.0% | 0.18% | -66.7% | |
| CDTX | CIDARA THERAPEUTICS INC | $2,863,000 | +11.1% | 250,000 | 0.0% | 0.18% | -6.3% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $2,812,000 | +29.9% | 390,000 | 0.0% | 0.18% | +10.0% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $2,652,000 | +11.4% | 73,000 | 0.0% | 0.17% | -5.7% | |
| GNCA | GENOCEA BIOSCIENCES INC | $2,458,000 | +24.9% | 480,000 | 0.0% | 0.15% | +5.5% | |
| SCYX | SCYNEXIS INC | $2,457,000 | +78.3% | 635,000 | 0.0% | 0.15% | +51.0% | |
| EGLTQ | EGALET CORP | $2,283,000 | +53.4% | 300,000 | 0.0% | 0.14% | +30.0% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $2,259,000 | +38.9% | 98,000 | 0.0% | 0.14% | +18.3% | |
| DMTX | DIMENSION THERAPEUTICS INC | $2,168,000 | +33.2% | 271,370 | 0.0% | 0.14% | +12.4% | |
| NVCR | NOVOCURE LTD | $1,830,000 | -26.8% | 214,316 | 0.0% | 0.12% | -37.8% | |
| NVAX | NOVAVAX INC | $1,773,000 | -71.4% | 852,500 | 0.0% | 0.11% | -75.8% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $1,731,000 | -28.1% | 165,000 | 0.0% | 0.11% | -38.8% | |
| CHMA | CHIASMA INC | $1,448,000 | +1.8% | 492,500 | 0.0% | 0.09% | -13.3% | |
| ANTH | ANTHERA PHARMACEUTICALS INC | $1,418,000 | +1.9% | 450,000 | 0.0% | 0.09% | -13.6% | |
| LIFE | ATYR PHARMA INC | $1,379,000 | +14.4% | 433,500 | 0.0% | 0.09% | -3.4% | |
| BLUE | BLUEBIRD BIO INC | $1,356,000 | +56.6% | 20,000 | 0.0% | 0.08% | +32.8% | |
| CERN | CERNER CORP | $1,235,000 | +5.4% | 20,000 | 0.0% | 0.08% | -11.5% | |
| WRIGHT MED GROUP INCnote 2.000% 2/1 | $1,073,000 | +16.8% | 1,000,000 | 0.0% | 0.07% | -1.5% | ||
| CERU | CERULEAN PHARMA INC | $654,000 | -50.6% | 625,000 | 0.0% | 0.04% | -58.2% | |
| INFI | INFINITY PHARMACEUTICALS INC | $421,000 | +17.3% | 270,000 | 0.0% | 0.03% | -3.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.